Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBMy name is Sam. I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, and I hate this disease. My life was extended by a bilateral lung transplant in July 2021, thanks to an unknown donor who gave me a gift for which the value cannot…. Read more. August 30, 2024 News by Lindsey Shapiro, PhD.
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the …
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. Immune cells separate IPF, fibrotic hypersensitivity pneumonitis September 6, 2024; Tales of 2 women, both named Melissa, on their IPF journeys September 3, 2024; Patient journeys highlighted for this year’s PF Awareness Month August 30, 2024 ‘You can’t have that’: The diet restrictions since my transplant August 27, 2024; Phase 1b trial …
Zelasudil wins FDA orphan drug status as IPF treatment candidate
WEBAug 25, 2023 · In preclinical models, zelasudil showed the ability to lessen scarring — and it was generally well tolerated in a Phase 1 study of healthy volunteers. “Selectively targeting ROCK2 is an exciting, novel approach which could provide a new treatment option for patients with IPF, and with potential applications in other interstitial lung diseases and …
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
What Is Pulmonary Fibrosis?
WEBSep 24, 2021 · Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung conditions collectively known as interstitial lung diseases (ILDs), many of which are known to cause progressive fibrosis.. Types and causes of …
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
Pulmonary Fibrosis Ups Risk of Pneumonitis for Some With Lung …
WEBNov 27, 2018 · The study “ Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis ” was published in the journal Lung Cancer. Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck’s Keytruda (pembrolizumab) are two programmed death-1 (PD-1) immune …
Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF
WEBJan 4, 2022 · Data on all-cause mortality were available for all but two of the 11 studies. Results of the mortality meta-analysis indicated that treatment with either Ofev or Esbriet reduced the risk of death by roughly 30%. Sub-analyses found that antifibrotic treatment significantly reduced mortality risk for people with idiopathic PF, but that the effect ...
Skip to content